Project Grant R03HL176624
Award Date
2/1/25
Completion Date
1/31/27
Dollars Obligated
$246K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21205, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $244,589.00 to investigate the role of the VPS34 protein in the development of pulmonary arterial hypertension (PAH). The research aims to examine the regulation and mechanisms of VPS34 activation in PAH, determine the impact of VPS34 on proliferation and survival of pulmonary artery vascular smooth muscle cells, and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $164,700 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to The Trustees of the University of Pennsylvania to study the role of mTOR hyperactivation in pulmonary vascular remodeling. The research aims to examine how mTOR activation in specific mesenchymal cell populations alters endothelial cell behavior and function, and how aberrant mTOR signaling contributes to pulmonary vascular remodeling. The project will...
This $242,310 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of NADPH oxidase 1 (NOX1) and AMP-activated protein kinase alpha-1 (AMPKA1) in the pathogenesis of pulmonary arterial hypertension (PAH). The research aims to determine how NOX1-mediated oxidation of AMPKA1 affects the CIP/KIP family of cyclin-dependent kinase inhibitors, specifically...
The National Heart, Lung, and Blood Institute (NHLBI) awarded National Jewish Health a $498,000 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) for the period of September 1, 2024 to August 31, 2027. The grant supports research to investigate the role of RNA editing, specifically the enzyme ADAR1, in regulating pulmonary artery endothelial cell function and its impact on the development of pulmonary hypertension, a fatal cardiovascular disease. The research aims to...
This $642,045 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand the role of right ventricular passive remodeling in ventricular-arterial uncoupling in pulmonary hypertension. The key objectives are to: Determine the mechanisms underlying elevations in the stiffness-to-contractility ratio (SCR) and resulting ventricular-arterial uncoupling. This involves separating...
This federal Project Grant award of $812,189 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to better understand pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD). The project aims to use advanced CT imaging to identify features that can predict the presence of pulmonary hypertension and distinguish between precapillary and postcapillary forms in COPD patients. The...
This $764,891 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) supports research to define a new lung-specific regulatory mechanism mediated by the protein BMPER for vascular remodeling during the progression of pulmonary hypertension associated with interstitial lung disease (ILD-PH). The project aims to: 1) define the transcriptional regulation of BMPER during ILD-PH progression; 2)...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to establish a pharmacokinetic model for absolute quantification of pulmonary perfusion and microvascular parameters, and validate this model in large animal models with independent tissue analyses. The total funding amount is $122,788, with a project period from September 15, 2024 to June 30, 2026. The key objectives are to provide a...
This $596,809.00 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to target the mitochondrial protein MitoNEET to address pulmonary hypertension (PH) secondary to lung disease (Group 3 PH). The research team at Emory University will conduct in vitro and in vivo studies to define how MitoNEET regulates pulmonary artery smooth muscle cell (PASMC) mitochondrial function and proliferation, as well...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $528,179 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Miami to conduct research on improving neovascularization (new blood vessel formation) in peripheral arterial disease and critical limb ischemia. The key objectives are to investigate: 1) whether extracellular vesicles mediate the systemic effect of ischemia training on reprogramming bone marrow-derived monocytes, 2) the role...